Is there any scoring system that can differentiate alcoholic cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with decompensated cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Validated Scoring System Exists to Differentiate Alcohol from MASLD in Decompensated Cirrhosis

There is currently no validated scoring system that can reliably differentiate alcoholic cirrhosis from MASLD in patients with decompensated cirrhosis. The available evidence shows that while some exploratory tools exist, none have been validated for this specific purpose in the decompensated setting.

Current Evidence Landscape

The EASL guidelines explicitly state that MELD remains the recommended prognostic tool for prediction of short-term mortality and morbidity in decompensated cirrhosis 1, but this score predicts outcomes rather than differentiating etiologies. The guidelines acknowledge that "we cannot at this point make any aetiology-specific recommendations regarding prognostic markers in alcohol-related, compensated liver disease" 1, and this limitation extends even more severely to decompensated disease.

Exploratory Tools Under Investigation

The ANI Score

A 2026 pilot study evaluated the ALD/NAFLD index (ANI) score in patients with steatotic liver disease 2. However, this study:

  • Only examined patients with MASLD (not decompensated cirrhosis)
  • Explicitly states "the ANI score is not validated to distinguish MetALD from MASLD" 2
  • Cannot be applied to your clinical scenario

AST/ALT Ratio

Recent comparative analysis suggests the AST/ALT ratio >1.5 was present in 62% of AFLD versus 28% of MASLD 3. While exploratory ROC analysis yielded an AUC of 0.88, this study:

  • Was cross-sectional with only 30 patients per group
  • Did not specifically examine decompensated cirrhosis
  • Requires external validation with objective alcohol biomarkers 3
  • Shows significant overlap between groups

Clinical Approach in Decompensated Cirrhosis

Since no scoring system can differentiate etiologies, diagnosis must rely on comprehensive alcohol assessment:

Alcohol Use Assessment (Essential)

  • Patient interview with validated questionnaires (AUDIT-C, CAGE)
  • Objective biomarkers: Phosphatidylethanol (PEth) testing is critical—it was positive in 69.4% of MetALD patients who might otherwise be misclassified 4
  • Serial measurements over ≥3 months to establish consumption patterns 5

Diagnostic Thresholds

According to the 2026 AGA Clinical Practice Update 5:

  • MASLD: <140 g/week (women) or <210 g/week (men)
  • MetALD: 140-350 g/week (women) or 210-420 g/week (men)
  • ALD: >350 g/week (women) or >420 g/week (men)

Biochemical Patterns (Suggestive but Not Diagnostic)

While not validated for differentiation in decompensated cirrhosis:

  • MASLD pattern: Higher ALT elevations, AST/ALT ratio typically <1 3
  • ALD pattern: AST/ALT ratio >1.5 more common, mild hypoalbuminemia 3
  • Critical caveat: These patterns overlap significantly and cannot be used alone for diagnosis

Important Clinical Pitfalls

  1. Liver stiffness measurements are unreliable during active alcohol use—they transiently increase stiffness values and should be interpreted cautiously 5

  2. Underreported alcohol consumption is common—PEth testing improved ascertainment of alcohol exposure and proper phenotyping 4

  3. MetALD represents a distinct high-risk phenotype—patients with both metabolic dysfunction and alcohol use have worse outcomes than MASLD alone, with 23% increased MACE and 34% increased mortality 6

  4. Prognostic scores differ from diagnostic scores—while MELD, CLIF-C-AD, and MELD-Na predict mortality in decompensated cirrhosis 1, 7, they do not differentiate etiology

Bottom Line for Clinical Practice

You cannot use a scoring system to differentiate these etiologies in decompensated cirrhosis. Instead, establish diagnosis through:

  1. Quantified alcohol consumption history over ≥3 months
  2. PEth testing for objective verification
  3. Assessment of cardiometabolic risk factors
  4. Recognition that many patients have overlapping etiologies (MetALD)

The distinction matters clinically because alcohol abstinence is independently associated with recompensation (sHR 1.87) and ongoing consumption increases mortality 5-fold 4, making accurate phenotyping essential for management rather than just prognostication.

Related Questions

What tests should be ordered to assess hepatic steatosis in a chronic alcoholic?
How is the Alcoholic/Non‑Alcoholic Fatty Liver Disease Index (ANI) calculated using AST, ALT, BMI, mean corpuscular volume, and the AST/ALT ratio, and how should the resulting score be interpreted to differentiate alcoholic from non‑alcoholic fatty liver disease?
What is the recommended management of alcoholic cirrhosis?
What are the recommended secondary prevention strategies for patients with chronic alcoholic liver disease?
How should a patient with alcoholic hepatitis who develops fever, chills, vomiting and markedly elevated AST (aspartate aminotransferase) and ALT (alanine aminotransferase) be managed?
How should prednisolone be administered to a 9‑month‑old infant weighing approximately 8.8 kg, and how often should it be given?
What is the recommended management for a patient with sick sinus syndrome presenting with symptomatic bradycardia, pauses, or syncope?
In the post‑resuscitation period after cardiac arrest, what systolic blood pressure should be maintained when using inotropes, fluids, and vasopressors?
In a patient with palpitations and an echocardiogram showing normal left‑ventricular function, mild atrial enlargement, grade I diastolic dysfunction, and trivial valve regurgitation, are these findings likely the cause of the palpitations, and what is the recommended next step in evaluation?
Can promethazine (antihistamine) with dextromethorphan be administered to a patient with congenital glaucoma?
In patients aged 18–50 years, ASA I–II undergoing laparoscopic cholecystectomy, should intravenous dexmedetomidine be used instead of fentanyl to attenuate haemodynamic responses to pneumoperitoneum, and what dosing regimen is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.